161 related articles for article (PubMed ID: 38301010)
1. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S; Bourcier J; Noviski M; Lu H; Thompson MC; Chirino A; Jahn J; Sondhi AK; Gajewski S; Tan YSM; Yung S; Urban A; Wang E; Han C; Mi X; Kim WJ; Sievers Q; Auger P; Bousquet H; Brathaban N; Bravo B; Gessner M; Guiducci C; Iuliano JN; Kane T; Mukerji R; Reddy PJ; Powers J; Sanchez Garcia de Los Rios M; Ye J; Barrientos Risso C; Tsai D; Pardo G; Notti RQ; Pardo A; Affer M; Nawaratne V; Totiger TM; Pena-Velasquez C; Rhodes JM; Zelenetz AD; Alencar A; Roeker LE; Mehta S; Garippa R; Linley A; Soni RK; Skånland SS; Brown RJ; Mato AR; Hansen GM; Abdel-Wahab O; Taylor J
Science; 2024 Feb; 383(6682):eadi5798. PubMed ID: 38301010
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E; Mi X; Thompson MC; Montoya S; Notti RQ; Afaghani J; Durham BH; Penson A; Witkowski MT; Lu SX; Bourcier J; Hogg SJ; Erickson C; Cui D; Cho H; Singer M; Totiger TM; Chaudhry S; Geyer M; Alencar A; Linley AJ; Palomba ML; Coombs CC; Park JH; Zelenetz A; Roeker L; Rosendahl M; Tsai DE; Ebata K; Brandhuber B; Hyman DM; Aifantis I; Mato A; Taylor J; Abdel-Wahab O
N Engl J Med; 2022 Feb; 386(8):735-743. PubMed ID: 35196427
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.
Robbins DW; Noviski MA; Tan YS; Konst ZA; Kelly A; Auger P; Brathaban N; Cass R; Chan ML; Cherala G; Clifton MC; Gajewski S; Ingallinera TG; Karr D; Kato D; Ma J; McKinnell J; McIntosh J; Mihalic J; Murphy B; Panga JR; Peng G; Powers J; Perez L; Rountree R; Tenn-McClellan A; Sands AT; Weiss DR; Wu J; Ye J; Guiducci C; Hansen G; Cohen F
J Med Chem; 2024 Feb; 67(4):2321-2336. PubMed ID: 38300987
[TBL] [Abstract][Full Text] [Related]
4. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
5. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
6. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
[TBL] [Abstract][Full Text] [Related]
7. Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).
Chirino A; Montoya S; Safronenka A; Taylor J
Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38137005
[TBL] [Abstract][Full Text] [Related]
8. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
9. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE; Burger JA
Front Immunol; 2021; 12():689472. PubMed ID: 34177947
[TBL] [Abstract][Full Text] [Related]
10. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V
Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730
[TBL] [Abstract][Full Text] [Related]
11. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Zhang D; Harris HM; Chen J; Judy J; James G; Kelly A; McIntosh J; Tenn-McClellan A; Ambing E; Tan YS; Lu H; Gajewski S; Clifton MC; Yung S; Robbins DW; Pirooznia M; Skånland SS; Gaglione E; Mhibik M; Underbayev C; Ahn IE; Sun C; Herman SEM; Noviski M; Wiestner A
Blood; 2023 Mar; 141(13):1584-1596. PubMed ID: 36375120
[TBL] [Abstract][Full Text] [Related]
12. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
15. Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Johnson AR; Kohli PB; Katewa A; Gogol E; Belmont LD; Choy R; Penuel E; Burton L; Eigenbrot C; Yu C; Ortwine DF; Bowman K; Franke Y; Tam C; Estevez A; Mortara K; Wu J; Li H; Lin M; Bergeron P; Crawford JJ; Young WB
ACS Chem Biol; 2016 Oct; 11(10):2897-2907. PubMed ID: 27571029
[TBL] [Abstract][Full Text] [Related]
16. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR
Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227
[TBL] [Abstract][Full Text] [Related]
17. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA
Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078
[TBL] [Abstract][Full Text] [Related]
18. BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma.
Yuan H; Zhu Y; Cheng Y; Hou J; Jin F; Li M; Jia W; Cheng Z; Xing H; Liu M; Han T
J Biol Chem; 2022 Nov; 298(11):102555. PubMed ID: 36183831
[TBL] [Abstract][Full Text] [Related]
19. Screening and monitoring of the BTK
Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
[TBL] [Abstract][Full Text] [Related]
20. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
